Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

193
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
193
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

682
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
682
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

254
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
254
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

246
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
246
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

319
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
319

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aeromonas Bacteremia in Pediatric Liver Transplant Recipients: Case-Based Experience of an Under-Recognized Infection.

Pediatric transplantation·2026
Same author

Impact of a pharmacist-led infectious disease support team on candidemia bundle adherence and 28-day mortality: a single-center retrospective cohort study.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2026
Same author

Optimization of Valganciclovir for Treatment of Cytomegalovirus Infection in Pediatric Liver Transplant Recipients: A Prospective Pharmacokinetic Study.

Transplantation direct·2026
Same author

Comparative Efficacy and Safety of 15-Valent and 13-Valent Pneumococcal Conjugate Vaccines Alone and in Combination with the 23-Valent Polysaccharide Vaccine: A Systematic Review and Meta-analysis.

Biological & pharmaceutical bulletin·2026
Same author

Role of pharmacists in providing information on cancer genome medicine and patient decision making: Open-label randomized controlled study.

Exploratory research in clinical and social pharmacy·2026
Same author

Three fluoroquinolones with different epithelial lining fluid penetration in a murine lung infection model: an experimental site-specific PK/PD study.

Antimicrobial agents and chemotherapy·2026

Related Experiment Video

Updated: Jan 17, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.1K

Development of Vancomycin Population Pharmacokinetic Models for Pediatric Patients Using a Real-World Web Application

Kazutaka Oda1,2, Kensuke Shoji3, Kazuaki Matsumoto4

  • 1Department of Pharmacy, Kumamoto University Hospital, 1-1-1 Honjo, Chuo-ku, Kumamoto city, Kumamoto 860-8556, Japan.

Journal of the Pediatric Infectious Diseases Society
|September 25, 2025
PubMed
Summary

A new population pharmacokinetic model for vancomycin dosing in Japanese children demonstrates excellent predictive performance. Two-point blood sampling is recommended for improved vancomycin clearance estimation in pediatric patients.

Keywords:
applicationarea under the concentration-time curvepopulation pharmacokineticsreal-world databasetherapeutic drug monitoringvancomycin

More Related Videos

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

1.8K
Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

14.6K

Related Experiment Videos

Last Updated: Jan 17, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.1K
A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

1.8K
Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

14.6K

Area of Science:

  • Pharmacology
  • Pediatric Medicine
  • Pharmacokinetics

Background:

  • The Japanese Society of Chemotherapy developed the practical area under the concentration-time curve (AUC)-guided therapeutic drug monitoring (PAT) application for vancomycin dosing.
  • PAT has generated a large real-world pharmacokinetic database in Japan.
  • Existing pediatric vancomycin models require optimization for Japanese children.

Purpose of the Study:

  • To develop a population pharmacokinetic (popPK) model for Japanese pediatric vancomycin dosing.
  • To compare the performance of the new model against existing models.

Main Methods:

  • Utilized a real-world database from 1673 Japanese pediatric patients (aged 3 months+) collected via PAT.
  • Performed population pharmacokinetic analysis using nonlinear mixed-effects modeling.
  • Compared the developed model against 5 existing pharmacokinetic models.

Main Results:

  • The developed popPK model showed strong a priori predictive performance for empirical vancomycin dosing (MPE: 0.2 μg/mL, MAPE: 5.6 μg/mL) with no bias.
  • Graphical diagnostics confirmed optimal a priori prediction.
  • Two-point vancomycin sampling yielded significantly different clearance estimates compared to one-point sampling in 18.1% of patients.

Conclusions:

  • The developed popPK model is suitable for both empirical and Bayesian-guided vancomycin dosing in Japanese pediatric patients (3 months+).
  • Two-point vancomycin sampling enhances clearance estimation accuracy and is recommended when feasible.